# Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
Canonical URL: https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-receives-tga-approval-of-redemplor-plozasiran-in-australia-expanding-global-access-for-patients-with-familial-chylomicronemia-syndrome-fcs
Ticker: ARWR
Company: Arrowhead Pharmaceuticals
Source: Arrowhead Pharmaceuticals
Published: 2026-05-01 11:30 EST
Original Source URL: https://ir.arrowheadpharma.com
## Summary

– REDEMPLO is the first and only medicine approved for use in the treatment of FCS in Australia, and is authorized for both genetically confirmed and clinically diagnosed adult patients with FCS – People living with FCS have extremely high triglyceride levels and a substantially higher risk of

## Article Body
– REDEMPLO is the first and only medicine approved for use in the treatment of FCS in Australia, and is authorized for both genetically confirmed and clinically diagnosed adult patients with FCS – People living with FCS have extremely high triglyceride levels and a substantially higher risk of
## Recent Company News
- 2026-06-02 11:30 EST — [Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-to-participate-in-upcoming-june-2026-events) — Source: Arrowhead Pharmaceuticals
- 2026-05-27 11:00 EST — [Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-presents-new-clinical-data-on-rnai-based-obesity-and-mash-candidate-aro-inhbe-at-easl-2026) — Source: Arrowhead Pharmaceuticals
- 2026-05-26 14:00 EST — [Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-presents-new-positive-clinical-cardiometabolic-data-at-the-94th-european-atherosclerosis-society-eas-congress) — Source: Arrowhead Pharmaceuticals
- 2026-05-07 20:01 EST — [Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-reports-fiscal-2026-second-quarter-results) — Source: Arrowhead Pharmaceuticals
- 2026-05-05 12:00 EST — [Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals](https://biopharmsignal.com/news/ARWR/arrowhead-pharmaceuticals-licenses-clinical-mash-program-targeting-pnpla3-to-madrigal-pharmaceuticals) — Source: Arrowhead Pharmaceuticals
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)